Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Susan Bergeson
Texas Tech University Health Scis Center, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
South Plains Biotechnology (SPB)
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The TTUHSC Conflict of Interest in Research Committee (COIRC) has determined that Dr. Bergeson has a conflict of interest as defined by TTUHSC OP 73.09, Conflict of Interest in Research, as a consequence of her interest in South Plains Biotechnology, Inc and the TTUS. The Conflict derives from the potential for her to benefit financially from South Plains Biotechnology, Inc. and IP ownership interests held by the TTU System Office of Research Commercialization that could be influenced by results of ongoing or proposed research.
Chemically modified minocycline for treatment of alcohol use disorder
Public Health Relevance Statement (Project Narrative) Alcohol Use Disorder (AUD) is a complex spectrum disorder that presents unmet clinical treatment challenges. Accumulating evidence indicates that the action of ethanol on the innate immune system leads to chronification of risky drinking, potential physical dependence, and often dangerous withdrawal symptoms. The proposed pre-clinical, IND-enabling project is a collaboration with NIAAA?s Division of Medications Development and addresses testing chemically modified minocycline analogs to prepare for Phase 1 of the FDA approval process.
Filed on November 01, 2018.
Tell us what you know about Susan Bergeson's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Susan Bergeson filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Susan Bergeson | Texas Tech University Health Scis Center | Conflict of Interest | Texas Tech University System | Value cannot be readily determined |
| Susan Bergeson | Texas Tech University Health Scis Center | Conflict of Interest | Texas Tech University System | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.